Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Evotec SE Earnings Release 2012

Nov 23, 2012

151_rns_2012-11-23_99f956c5-e5f1-4663-8956-757243260ffe.html

Earnings Release

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

News Details

Corporate | 23 November 2012 07:30

Evotec Receives CIR (French Research Tax Credit) Accreditation

Evotec AG / Key word(s): Miscellaneous

23.11.2012 / 07:30


Hamburg, Germany - 23 November 2012: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX) today announced that it has received CIR accreditation for a
three-year period from the French Ministry of Higher Education and
Research.

The French R&D tax credit initiative ('Crédit d'Impôt Recherche', CIR)
gives eligible research-based French companies, who are subject to
corporate tax in France, the ability to claim tax relief on costs generated
in R&D activities outsourced to Evotec.

Dr Mario Polywka, Chief Operating Officer of Evotec AG, commented: 'We are
delighted to receive this accreditation as it allows our current and future
customers in France to benefit from a tax relief of up to 30% of their R&D
expenditure committed to Evotec.'

About CIR
The Research Tax Credit (CIR) is a central tool of the policy favouring
research and innovation. This tax benefit allows the growth of businesses
competitiveness by favouring research and development. It is particularly
adapted to the needs of small and medium-sized enterprise and constitutes a
reliable element of the innovative business financing plan.
(www.eureka.lorraine.eu)

FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.

Contact Evotec AG:
Dr Mario Polywka, Chief Operating Officer, Phone: +44.(0)1235.441676,
[email protected]

End of Corporate News


23.11.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de


Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart

End of News DGAP News-Service

194417 23.11.2012